| FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $377.1M | ||||
Company | Location |
Date | Amt. (M) |
Details |
Affiris GmbH |
Vienna, Austria | 4/6/06 |
€8.5 ($10.3) |
MIG Funds was the sole investor in the Series A, milestone-driven funding round |
Affitech A/S |
Oslo, Norway |
4/9/06 |
NOK86 ($13) |
Participating in the financing round were existing investors Teknoinvest, Ferd Venture, Four Seasons Venture and Braganza AS, along with new investor Arendals Fossekompani |
CFD |
South San Francisco |
3/30/06 |
ND |
The DiaDexus Inc. spinoff was formed along with Biotechnology Value Fund LP, which provided an initial investment and gained a majority interest |
Chroma |
Oxford, UK |
4/3/06 |
$53 |
The Series C financing was led by Nomura Phase4 Ventures and included existing investors Abingworth Management, Essex Woodlands Healthcare Ventures, Gilde Healthcare and the Wellcome Trust |
Cougar |
Los Angeles |
4/10/06 |
$47.5 |
The financing was made in conjunction with its merger with the public shell company SRKP 4 Inc.; Adage Capital Management LP was lead investor; others included Brookside Capital, funds managed by T. Rowe Price Associates, Merlin Biomed Group, RA Capital Management and Tavistock Life Sciences; Cowen & Co. LLC and Paramount BioCapital Inc. were co-placement agents |
Hunter-Fleming |
Bristol, UK |
4/3/06 |
£15.5($27) |
The £6.9M Series B portion of the financing was led by MTI Partners Ltd. and included Advent International, ITX Corp., Omega Fund Management, Pharmabio Development and Finance South West Growth Fund; the remaining funds will be used to set up a joint venture, Trident Pharmaceuticals Inc., which was financed by Advent and Omega |
Ingenium |
Munich, Germany |
4/4/06 |
€9.2 ($11.1) |
The first closing of the Series D financing round was led by existing investors HBM Bioventures Ltd. andTVM Capital |
Innodia Inc. |
Montreal |
4/3/06 |
C$10 ($8.7) |
Purchasing the convertible debentures were existing shareholders Picchio Pharma, CDP Capital, the Business Development Bank of Canada and private investors, and new investors the Solidarity Fund QFL and Fondaction CSN |
Merrimack |
Cambridge, Mass. |
4/3/06 |
$65 |
The Series E financing round included new investors Jennison Associates, Modal Capital, funds advised by Noonday Asset Management LP, TPG-Axon Capital, and existing investors Sorenson Development and WT Investment Advisors Fund LLP |
NeuroHealing |
Newton, Mass. |
4/5/06 |
$0.5 |
Life Science Angels Inc. is investing up to $0.5M in NeuroHealing |
N-Gene |
New York |
4/6/06 |
$3 |
Corvinus Venture Capital Funds Management Ltd. provided the funding in the what was expected to be the first part of a Series B round |
Novagali |
Evry, France |
4/12/06 |
€26 ($31.4) |
AGF Private Equity and Bernard Chauvin joined existing investors 1.2.3. Multinova, Auriga Partners, CDC Entreprises Innovation, Credit Agricole Private Equity, Edmond de Rothschild Investment Partners, FCJE managed by CDC Entreprises-FP Gestion and Siparex Ventures in the financing round |
Peakadilly NV |
Ghent, Belgium |
4/19/06 |
€6 ($7.4) |
The first close of the Series A financing was led by Life Science Partners, and co-led by Johnson & Johnson Development Corp. |
Protez |
Malvern, Pa. |
4/25/06 |
$6 |
The $6M investment from Easton Capital Investment Group and current investors capped the company's Series B round at $21M; it raised $15M in August 2005 in the first Series B tranche |
Sirtris |
Cambridge, Mass. |
4/20/06 |
$37 |
A $22M Series C round was led by new investor Bessemer Venture Partners and included Genzyme Ventures, QVT Fund LP, Alexandria Real Estate Equities Inc. and all existing investors; Sirtris also secured $15 million in debt financing from Hercules Technology Growth Capital, of which it initially is drawing down $10M |
SkinMedica |
Carlsbad, Calif. |
4/11/06 |
$11.2 |
The Series E-1 financing round was led by Montagu Newhall Associates and included existing investors Domain Associates, Apax Partners, Perseus-Soros Biopharmaceutical Fund, HealthCare Ventures, EuclidSR Partners and Montreux Equity Partners |
Theranox |
Philadelphia |
4/10/06 |
$14 |
The Series A financing round was led by Quaker BioVentures and NewSpring Capital |
Xenon |
Vancouver, British Columbia |
4/11/06 |
$31 |
The third-round financing was led by MX Associates LLP and LipoteRx Ltd., and included INVESCO Private Capital |
Notes: | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
